Co-Diagnostics, Inc. Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $166,000, a slight increase from $163,000 year-over-year.

Gross Profit: Approximately $121,000, down from $131,000 in the prior year.

Operating Expenses: $6.3 million, reduced from $8.2 million in Q2 2025, primarily due to lower general and administrative and R&D expenses.

Net Loss: $6.3 million, or $1.46 per share, improved from a net loss of $7.7 million, or $7 per share, in the same period last year.

Adjusted EBITDA: Loss of $5.8 million, compared to a loss of $7.2 million in Q2 2025.

Cash and Cash Equivalents: $3.6 million at quarter-end, down from $11.9 million at the end of 2025.

2Strategic Updates and Business Highlights

Regulatory Milestones: Successful completion of analytical and clinical performance studies for the upper respiratory multiplex assay, leading to a dual 510(k) and CLIA-waived application submission to the FDA.

Tuberculosis Program: Progress in India with plans for submissions to the CDSCO and WHO's ERPD later this year.

Ebola Testing: Completed proof of concept for an Ebola assay, demonstrating the platform's flexibility.

Digital Infrastructure: Continued development of a connected ecosystem for molecular diagnostics, integrating AI capabilities.

International Expansion: Advancements in the CoMira joint venture in Saudi Arabia, focusing on localized manufacturing and commercialization.

3Forward Guidance and Outlook

Co-Diagnostics anticipates continued operating losses in the near term but remains focused on advancing clinical pipelines and regulatory submissions to position the business for future revenue growth.

The company is exploring various capital sources, including equity and debt financing, while prioritizing nondilutive funding options like grants.

4Bad News, Challenges, or Points of Concern

Limited Revenue Levels: Current revenue remains low, impacting overall financial performance.

Cash Burn: Significant decrease in cash reserves raises concerns about liquidity and funding for ongoing projects.

Operating Losses: Despite reduced losses, the company continues to operate at a net loss, which may pose challenges in sustaining long-term growth without additional funding.

5Notable Q&A Insights

Tuberculosis ERPD Assessment: Confirmed plans to submit for ERPD assessment later this year, indicating progress in their TB program.

Ebola Strategy: The company is prepared to respond quickly to Ebola outbreaks, with ongoing development efforts and recent requests for test evaluations from Indian authorities. Overall, Co-Diagnostics is making strides in regulatory and clinical advancements, although financial performance remains a concern with ongoing losses and reduced cash reserves. The company is strategically positioned for future growth but must navigate challenges related to funding and market entry.